Swiss biotech group Actelion Ltd (ATLN.VX) won the support of one of its biggest shareholders on Monday in its war of words with activist fund Elliott Advisers, which has called on Actelion to consider putting itself up for sale. "Actelion has the right strategy in place to ensure sustained value creation," Rudolf Maag, who holds 4.2 percent of Actelion's outstanding shares, said in a statement. "The company enjoys a strong, risk-balanced pipeline and invests the shareholder's money in the right projects ... I am convinced that pursuing a stand-alone strategy where the benefits of these investments can be fully realized will maximise shareholder value over the medium to long term."
Source
